Infectious Disease Practice Startup Consultant Services

An infectious disease practice startup consultant helps evaluate the operational and financial structure of a new practice. Support may include payer enrollment, physician and APP credentialing, referral workflows, documentation, coding, eligibility, authorization, drug and infusion billing, claims processes, staffing considerations, and revenue cycle planning. The goal is to help practice leaders understand how clinical services translate into sustainable operations.

Preparation involves reviewing the full workflow from referral and eligibility through authorization, drug acquisition, first dose, documentation, billing, payment, and follow-up. Infusion and OPAT services may involve different payer requirements and benefit structures than office or consult work. A structured review can identify responsibilities, control points, documentation needs, and revenue risks before the service is launched.

Revenue cycle consulting can cover documentation and coding, eligibility and prior authorization, charge capture, drug and infusion billing, claim submission, rejection clearing, denial management, underpayment review, accounts receivable follow-up, and payer or hospital coverage agreements. The work is designed to trace revenue gaps to their source and prioritize practical workflow improvements for the practice.

Payer enrollment is necessary for the relevant physicians, advanced practice providers, sites, and billable services to be recognized by participating payers. Infectious disease practices may have separate revenue streams for office visits, hospital consults, infusion, OPAT, and contracted work. Reviewing each stream helps prevent a practice from beginning services before its enrollment and credentialing requirements are addressed.

Yes. Revenue leakage can occur through under-leveled visits, missed drug or administration charges, documentation gaps, coding problems, contract issues, unworked denials, short payments, and aging balances. A review can organize reporting by payer, service line, and provider, then connect missing or delayed revenue to documentation, charge capture, authorization, claims, payment, or workflow causes.

Payment reconciliation compares received payments with expected reimbursement for drug, administration, and evaluation and management claims. The review can flag short-pays, incorrect fee schedule application, unit mismatches, and NDC mismatches. Findings are documented for dispute and follow-up, helping the practice understand whether contract terms, claim details, or payer processing contributed to the underpayment.

Yes. Support may address claims management, overflow work, rejection clearing, denial appeals, and aging accounts receivable. Claims can be reviewed across evaluation and management, infusion, and drug services, while A/R follow-up can be organized by payer, service type, and balance. The objective is both to resolve outstanding work and identify recurring process issues.

GrowInfectiousDisease does not publish invented rates, drug acquisition costs, payment rates, or margin figures. Its tools and guidance are designed to help users apply their own numbers and assess practice-specific assumptions. The editorial approach distinguishes verified information from unknown or local variables, so physicians and administrators can evaluate financial sustainability with appropriate caution.